
Increasingly versatile peptide drugs for diabetes
Diabetes affects an estimated 37 million Americans. The disease affects the body’s control of circulating sugar, usually through changes in tissue responses to insulin.
Incretins, peptide hormones that influence insulin secretion, have emerged in recent decades as drug targets for diabetes. Glucagon-like peptide 1 receptor agonists, peptide drugs that mimic the incretin GLP-1, improve glycemic control among diabetic patients. But they are less effective than the much more invasive treatment of bariatric surgery, which leaves pharmaceutical researchers wondering whether these drugs can be improved.
Scientists have looked to other incretins, beginning with glucose-dependent insulinotropic polypeptide, or GIP. GLP-1 and GIP have a similar alpha-helical structure and significant sequence overlap, and both are released from the gastrointestinal tract to reduce circulating glucose by stimulating insulin secretion.

This year, the U.S. Food and Drug Administration approved the first peptide drug that works as a bifunctional agonist of both GLP-1 and GIP receptors. The drug, tirzepatide, causes weight loss and improves cardiometabolic and glycemic outcomes in diabetic patients. Its amino acid sequence, based on GIP, is engineered to bind both GIP and GLP-1 receptors, with modifications to boost its half-life by reducing its susceptibility to proteases and improving its binding to albumin.
Meanwhile, industrial research labs are looking to expand from bifunctional to trifunctional peptide drugs that target GLP-1, GIP and also glucagon receptors. Adding glucagon to the mix is expected to have complementary effects on glycemic control, obesity and diabetes. Researchers at Eli Lilly and Company wrote in a statement to ASBMB Today, “Our hypothesis considers that GLP-1 reduces appetite and GIP enhances GLP-1-induced reduction of appetite and glucagon enhances energy expenditure and combination of all those effects may produce more weight loss.”
This year, two papers published in the journal Cell Metabolism reported on trifunctional agonists that can activate all three receptors. Both drugs’ sequences use insights from alignment and 3D structural examination to merge the features of each peptide that are important for receptor binding and balance potency against all three receptors. In obese mice and monkeys, the triple agonists reduced body weight even in animals that lacked the GLP-1 receptor.
Both drugs were tested in humans in small preliminary trials. Sanofi discontinued work on its drug in 2019 after the preliminary human trial; Eli Lilly has continued to develop its drug, with two effectiveness and safety trials set to begin this year. These may be the first of many; in their paper, the Lilly scientists observed that “targeting all 3 of these receptors has evolved into the next generation of drug development for treatment of T2D and obesity.”
Enjoy reading ASBMB Today?
Become a member to receive the print edition monthly and the digital edition weekly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Opinions
Opinions highlights or most popular articles

An open letter to the ASBMB executive director search committee
"As you sift through the applications ... look for signs of altruism, vision and an investment mentality rather than the extent of administrative experience and managerial acumen," Pete Kennelly writes.

Scientific publishing, then and now
Fifty years ago, “editors provided constructive feedback that improved our manuscripts,” Sudhansu K. Dey writes. That happens less nowadays.

On our wall: A bird’s eye view of metabolism
To understand the complex relationships of the metabolic cycles and pathways, it helps to have the big picture, so a professor and students in Pakistan created one.

Wellness and trauma
Telling stories helps us heal. Here’s my trauma story. Now I want to read yours.

An ancient practice in need of modern-day support
August is National Breastfeeding Month.

Exploring careers in microscopy
During a mini-internships, Laura McCormick learned about working at a core facility and for a manufacturer.